Herpes simplex virus vectors for Parkinson's disease

International Review of Neurobiology

Volumn 55, Issue , 2003, Pages 223-241

  Latchman, David S ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMAL; GENE THERAPY; GENE VECTOR; GENETICS; HERPES SIMPLEX VIRUS; HUMAN; METHODOLOGY; PARKINSON DISEASE; REVIEW;

ANIMALS; GENE THERAPY; GENETIC VECTORS; HUMANS; PARKINSON DISEASE; SIMPLEXVIRUS;

EID: 0141483402     PISSN: 00747742     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S0074-7742(03)01010-9     Document Type: Article

References (60)

1. Abeliovich, A., Schmitz, Y., Fariñas, I., Choi-Lundberg, D., Ho, W.-H., Castillo, P. E., Shinsky, N., Garcia Verdugo, J. M., Armanini, M., Ryan, A., Hynes, M., Phillips, H., Sulzer, D., and Rosenthal, A. (2000). Mice lacking α-synuclein display functional deficits in the nigrostriatal dopamine system. Neuron 25, 239-252.
2. Ace, C. I., McKee, T. A., Ryan, M., Cameron, J. M., and Preston, C. M. (1989). Construction and characterization of a herpes simplex virus type I mutant unable to transduce immediate-early gene expression. J. Virol. 63, 2260-2269.
3. Bencsjcs, C., Wachtel, S. R., Milstien, S., Hatakeyama, K., Becker, J. B., and Kang, U. J. (1996). Double transduction with GTP cyclohydrolase I and tyrosine hydroxylase is necessary for spontaneous synthesis of L-DOPA by primary fibroblasts. J. Neurosci. 16, 4449-4456.
4. Bilang-Bleuel, A., Revah, F., Colin, P., Locquet, I., Robert, J.-J., Mallet, J., and Horellou, P. (1997). Intrastriatal injection of an adenoviral vector expressing glial-cell-line-derived neurotrophic factor prevents dopaminergic neuron degeneration and behavioural impairment in a rat model of Parkinson disease. Proc. Nat. Acad. Sci. USA 94, 8818-8823.
5. Chiocca, A. E., Choi, B. B., Cai, W., DeLuca, N., Schaffer, P. A., DiFiglia, M., Breakfield, X. O., and Martuza, R. L. (1990). Transfer and expression of the lac Z gene in rat brain neurons by herpes simplex virus mutants. New Biol. 266, 739-746.
6. Clayton, D. F., and George, J. M. (1999). Synucleins in synaptic plasticity and neurodegenerative disorders. J. Neurosci. Res. 58, 120-129.
7. Coffin, R. S., Maclean, A. R., Latchman, D. S., and Brown, S. M. (1996). Gene delivery to the central and peripheral nervous systems of mice using HSV1 ICP34.5 deletion mutant vectors. Gene Ther. 3, 886-891.
8. de Silva, R.H.A., Khan, N. L., and Wood, N. W. (2000). New developments in the genetics of Parkinson's disease. Curr. Opin. Genet. Dev. 10, 292-298.
9. Dobson, A. T., Margolis, T. P., Sedarati, F., Stevens, J. G., and Feldman, L. T. (1990). A latent nonpathogenic HSV-1 derived vector stably expresses β galactosidase in mouse neurons. Neuron 5, 353-360.
10. Dobson, A. T., Margolis, T. P., Gomes, W. A., and Feldman, L. T. (1995). In vivo deletion analysis of the herpes simplex virus type 1 latency associated transcript promoter. J. Virol. 69, 2264-2270.
11. During, M. J., Naegele, J. R., O'Malley, K. L., and Geller, A. I. (1994). Long-term behavioural recovery in parkinsonian rats by an HSV vector expressing tyrosine hydroxylase. Science 266, 1399-1403.
12. Feany, M. B., and Bender, W. W. (2000). A Drosophila model of Parkinson's disease. Nature 404, 394-398.
13. Fink, D. J., DeLuca, N. A., Goins, W. F., and Glorioso, J. C. (1996). Gene transfer to neurons using herpes simplex virus-based vectors. Annu. Rev. Neurosci. 19, 265-287.
14. Freed, C. R., Greene, P. E., Breeze, R. E., Tsai, W.-Y., DuMouchel, W., Kao, R., Dillon, S., Winfield, H., Culver, S., Trojanowski, J. Q., Eidelberg, D., and Fahn, S. (2001). Transplantation of embryonic dopamine neurons for severe Parkinson's disease. N. Engl. J. Med. 344, 710-719.
15. Freese, A., Stern, M., Kaplitt, M. G., O'Connor, W. M., Abbey, M. V., O'Connor, M. J., and During, M. J. (1996). Prospects for gene therapy in Parkinson's disease. Mov. Disord. 11, 469-488.
16. French Anderson, W. (1998). Human gene therapy. Nature. 392(Suppl.), 25-30.
17. Goding, C. R., and O'Hare, P. (1989). Herpes simplex virus Vmw65-octamer binding protein interaction: A paradigm for combinatorial control of transcription. Virology 173, 363-367.
18. Goins, W. F., Stenberg, L. R., Croen, K. D., Krause, P. R., Hendricks, R. L., Fink, D. J., Straus, S. E., Levine, M., and Gloriso, J. C. (1994). A novel latency-associated promoter is contained within the herpes simplex virus type 1 UL Hanking repeats. J. Virol. 68, 2239-2252.
19. Ho, D. Y., and Mocarski, E. S. (1989). Herpes simplex virus latent RNA (Lat) is not required for latent infection in the mouse. Proc. Natl. Acad. Sci. USA 86, 7596-7600.
20. Horellou, P., Vigne, E., Castel, M. N., Barneoud, P., Colin, P., Perricaudet, M., Delare, P., and Mallet, J. (1994). Direct intracerebral gene transfer of an adenoviral vector expressing tyrosine hydroxylase in a rat model of Parkinson's disease. NeuroReport 6, 49-53.
21. Howard, M. K., Kershaw, T., Gibb, B., Storey, W., Maclean, A. R., Zeng, B.-W., Jenner, P., Brown, S. M., Woolf, C. J., Anderson, P. N., Coffin, R. S., and Latchman, D. S. (1998). High efficiency gene transfer to the central nervous system of rodents and primates using herpes virus vectors lacking functional ICP27 and ICP34.5. Gene Ther. 5, 1137-1147.
22. Hynes, M., Porter, J. A., Chiang, C., Chang, D., Tessier-Lavigne, M., Beachy, P. A., and Rosenthal, A. (1995). Induction of midbrain dopaminergic neurons by sonic hedgehog. Neuron 15, 35-44.
23. Kaplitt, M. G., Leone, P., Samulski, R. J., Xiao, X., Pfaff, D. W., O'Malley, K. L., and During, M. J. (1994). Long-term gene expression and phenotypic correction using adeno-associated virus vectors in the mammalian brain. Nat. Genet. 8, 148-154.
24. Kennedy, G. E. (1997). Potential use of herpes simplex virus (HSV) vectors for gene therapy of neurological disorders. Brain 120, 1245-1259.
25. Kitada, T., Asakawa, S., Hattori, N., Matsumine, H., Yamamura, Y., Minoshima, S., Yokochi, M., Mizuno, Y., and Shimizu, N. (1998). Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature 392, 605-608.
26. Kordower, J. H., Palfi, S., Chen, E.-Y., Ma, S. Y., Sendera, T., Cochran, E. J., Mufson, E. J., Penn, R., Goetz, C. G., and Comella, C. D. (1999). Clinicopathological findings following intraventricular glial-derived neurotrophic factor treatment in a patient with Parkinson's disease. Ann. Neurol. 46, 419-424.
27. Krüger, R., Kühn, W., Müller, T., Woitalla, D., Graeber, M., Kösel, S., Przuntek, H., Epplen, J. T., Schöls, L., and Riess, O. (1998). Ala30P mutation in the gene encoding α-synuclein in Parkinson's disease. Nat. Genet. 18, 106-108.
28. Lapchak, P. A. (1996). Therapeutic potentials for glial cell line-derived neurotrophic factor (GDNF) based upon pharmacological activities in the CNS. Rev. Neurosci. 7, 165-176.
29. Lapchak, P. A., Miller, P. J., Jiao, S. S., Araujo, D. M., Hilt, D., and Collins, R. (1996). Biology of glial cell line-derived neurotrophic factor (GDNF): Implications for the use of GDNF to treat Parkinson's disease. Neurodegeneration 5, 197-205.
30. Latchman, D. S. (1990). Molecular biology of herpes simplex virus latency. Int. J. Exp. Pathol. 71, 133-141.
31. Latchman, D. S. (2001). Gene delivery and gene therapy with herpes simplex virus based vectors. Gene 264, 1-9.
32. Leroy, E., Boyer, R., and Auburger, G. (1998). The ubiquitin pathway in Parkinson's disease. Nature 395, 451-152.
33. Lilley, C. E., Groutsi, F., Han, Z. Q., Palmer, J. A., Anderson, P. N., Latchman, D. S., and Coffin, R. S. (2001). Multiple immediate-early gene-deficient herpes simplex virus vectors allowing efficient gene delivery to neurons in culture and widespread gene delivery to the central nervous system in vivo. J. Virol. 75, 4343-4356.
34. Lin, L.-F.H., Doherty, D. H., Lile, J. D., Bekthesh, S., and Collins, F. (1993). A glial cell-derived neurotrophic factor for midbrain dopaminergic neurons. Science 260, 1130-1132.
35. Lindvall, O., Brundin, P., Widner, H., Rhencrona, S., Gustavii, B., Fracowiak, R., Leenders, K. L., Sawle, G., Rothwell, J. C., Marsden, G. D., and Bjorklund, A. (1996). Grafts of fetal dopamine neurons survive and improve motor function in Parkinson's disease. Science 247, 574-577.
36. Lucking, C. B., Dürr, A., Bonifati, V., Vaughan, J., De Michele, G., Gasser, T., Harhangi, B. S., Meco, G., Denèfle, P., Wood, N. W., Agid, Y., and Brice, A. (2000). Association between early-onset Parkinson's disease and mutations in the Parkin gene. N. Engl. J. Med. 342, 1560-1567.
37. Maclean, A. R., Fareed, M. U., Robertson, L., Harland, J., and Brown, S. M. (1991). Herpes simplex virus type 1 deletion variants 1714 and 1716 pinpoint neurovirulence related sequences in Glasgow strain 17+ between immediate-early gene 1 and the 'a' sequence. J. Gen. Virol. 72, 631-639.
38. Mandel, R. J., Rendahl, K. G., Spratt, S. K., Snyder, R. O., Cohen, L. K., and Leff, S. E. (1998). Characterization of intrastriatal recombinant adeno-associated virus-mediated gene transfer of human tyrosine hydroxylase and human GTP-cyclohydrolase I in a rat model of Parkinson's disease. J. Neurosci. 18, 4271-4284.
39. Margolis, T. P., Sedarati, F., Dobson, A. T., Feldman, L. T., and Stevens, J. G. (1992). Pathways of viral gene expression during acute neuronal infection with HSV-1. Virology 189, 150-160.
40. Margolis, T. P., Bloom, D. C., Dobson, A. T., Feldman, L. T., and Stevens, J. G. (1993). Decreased reporter gene expression during latent infection with HSV LAT promoter constructs. Virology 197, 585-592.
41. Masliah, E., Rockenstein, E., Veinbergs, I., Mallory, M., Hashimoto, M., Takeda, A., Sagara, Y., Sisk, A., and Mucke, L. (2000). Dopaminergic loss and inclusion body formation in β-synuclein mice: Implications for neurodegenerative disorders. Science 287, 1265-1269.
42. Miller, A. D. (1992). Human gene therapy comes of age. Nature 357, 455-460.
43. Natsume, A., Mata, M., Goss, J., Huang, S., Wolfe, D., Oligino, T., Glorioso, J., and Fink, D. J. (2001). Bcl-2 and GDNF delivered by HSV-mcdiated gene transfer act additively to protect dopaminergic neurons from 6-OHDA-induced degeneration. Exp. Neurol. 169, 231-238.
44. Olanow, C. W., Kordower, J. H., and Freeman, T. B. (1996). Fetal nigral transplantation as a therapy for Parkinson's disease. Trends Neurosci. 19, 102-109.
45. Palmer, J., Branston, R., Lilley, C. E., Robinson, M., Groutsi, F., Smith, J., Latchman, D. S., and Coffin, R. S. (2000). Development and optimisation of herpes simplex virus vectors for multiple long term gene delivery to the peripheral nervous system. J. Virol. 74, 5604-5618.
46. Polymeropoulos, M. H., Lavedan, C., Leroy, E., Ide, S. E., Dehejia, A., Dutra, A., Pike, B., Root, H., Rubenstein, J., Boyer, R., Stenroos, E. S., Chandrasekharappa, S., Athanassiadou, A., Papapetropoulos, T., Johnson, W. G., Lazzarini, A. M., Duvoisin, R. C., Di Iorio, G., Golbe, L. I., and Nussbaum, R. L. (1997). Mutation in the α-synuclein gene identified in families with Parkinson's disease. Science 276, 2045-2047.
47. Rampling, R., Cruickshank, G., Papanastassiou, V., Nicoll, J., Hadley, D., Brennan, D., Petty, R., Maclean, A., Harland, J., McKie, E., Mabbs, R., and Brown, M. (2000). Toxicity evaluation of replication-competent herpes simplex virus (ICP 34.5 null mutant 1716) in patients with recurrent malignant glioma. Gene Ther. 7, 859-866.
48. Riess, O., Jakes, R., and Krüger, R. (1998). Genetic dissection of familial Parkinson's disease. Mol. Med. Tody 4, 438-444.
49. Roizman, B., and Sears, A. E. (1987). An inquiry into the mechanisms of herpes simplex virus latency. Annu. Rev. Microbiol. 41, 543-571.
50. Sacks, W. R., Greene, C. C., Aschmann, D. P., and Schaffer, P. A. (1985). Herpes simplex virus type 1 ICP27 is an essential regulatory protein. J. Virol. 55, 796-805.
51. Shimura, H., Hattori, N., Kubo, S.-I., Mizuno, Y., Asakawa, S., Minoshima, S., Shimizu, N., Iwai, K., Chiba, T., Tanaka, K., and Suzuki, T. (2000). Familial Parkinson disease gene product, parkin, is a ubiquitin-protein ligase. Nat. Genet. 25, 302-305.
52. Smith, M. D., Ensor, E. A., Coffin, R. S., Boxer, L. M., and Latchman, D. S. (1998). Bcl-2 transcription from the proximal p2 promoter is activated in neuronal cells by the Brn-3a POU family transcription factor. J. Biol. Chem. 273, 16715-16722.
53. L and promotes neuronal survival in vivo as well as in vitro. Mol. Cell. Neurosci. 17, 460-470.
54. Spillantini, M. G., Schmidt, M. L., Lee, V.M.Y., Trojanowski, J. Q., Jakes, R., and Goedert, M. (1997). α-Synuclein in Lewy bodies. Nature 388, 839-840.
55. Spillantini, M. G., Crowther, R. A., Jakes, R., Hasegawa, M., and Goedert, M. (1998). α-Synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with Lewy bodies. Proc. Nat. Acad. Sci. USA. 95, 6469-6473.
56. Thomas, S. K., Lilley, C. E., Latchman, D. S., and Coffin, R. S. (1999). Equine herpes virus 1 gene 12 can substitute for Vmw65 in the growth of herpes simplex virus 1 (HSV1) allowing the generation of optimised cell lines for the propagation of vectors with multiple immediate-early gene defects. J. Virol. 79, 7399-7409.
57. Wagstaff, M. J. D., Collaco-Moraes, Y., Smith, J., de Belleroche, J., Coffin, R. S., and Latchman, D. S. (1999). Protection of neuronal cells from apoptosis by hsp27 delivered with a herpes simplex virus-based vector. J. Biol. Chem. 274, 5061-5069.
58. Wang, Q., Guo, J., and Jia, W. (1997). Intracerebral recombinant HSV-1 vector does not reactivate latent HSV-1. Gene Ther. 4, 1300-1304.
59. Widner, H., Tetrud, J., and Rehncrona, S. (1992). Bilateral fetal mesencephalic grafting in two patients with parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). N. Eng. J. Med. 327, 1556-1563.
60. Yamada, M., Oligino, T., Mata, M., Goss, J. R., Glorioso, J. C., and Fink, D. J. (1999). Herpes simplex virus vector-mediated expression of Bcl-2 prevents 6-hydroxydopamine-induced degeneration of neurons in the substantia nigra in vivo. Proc. Nat. Acad. Sci. USA 96, 4078-4083.